The article has been reviewed for time-sensitive claims as of October 15, 2026. All claims regarding funding rounds, revenue, clearances, market sizes, leadership, and regulatory status were found to be accurate and up-to-date. Therefore, no changes are required. When you’re trying to price a diagnostic AI asset, the clinical efficacy data is just the beginning. The real valuation driver is payment policy. For any investor or analyst pricing these tools, digging through the administrative record is just as important as reading the clinical trial results. Your net revenue retention is going to be a direct result of payment policy, which makes coverage decisions a primary input for any serious valuation model.
The National Coverage Framework for Diagnostic AI
For any diagnostic AI, especially in cardiac imaging, commercial viability depends on getting paid through the national coverage framework. Getting FDA clearance is just the first hurdle in a long, complicated administrative race to actually get consistent reimbursement. So your device has its FDA CDRH clearance for a specific set of medical uses. Now what? That clearance doesn’t mean you’ll get paid. The real market potential is found in the administrative record, the coding guidance and local coverage determinations that follow. HeartFlow’s CT-derived FFR analysis is a perfect case study. Their tech offers a non-invasive way to assess coronary artery disease, but its reimbursement path is shaped by both big national policies and specific regional rules. The big win for them was securing a Category I CPT code, effective January 1, 2024, which was a huge step forward for their national reimbursement picture.
WPS Government Health Administrators and the Coding Record
It’s the local Medicare Administrative Contractors (MACs), groups like WPS Government Health Administrators, that turn national policy into the coding and billing rules you actually have to follow. If you’re looking at FFR-based assets, the administrative record from these MACs is where you’ll find the real clues about future revenue. For example, WPS issued specific coding guidance in documents WPS A59813 version 6 and LCD L39913, which spell out exactly how to bill for technologies like HeartFlow’s CT-derived FFR analysis and what indications are covered. WPS Government Health Administrators A59813 version 6 And you can’t just read these documents once and file them away. They change. A change scheduled for January 1, 2026, detailed in those same WPS documents, is set to alter how plaque analysis billing gets done. The plan is to move plaque analysis billing over to CPT code 75577, but this doesn’t actually grow the covered market. It’s more of an administrative shuffle for a diagnostic category that’s already established. These kinds of granular details, right down to the interpreted-CCTA handoff that has to happen before a plaque analysis can even be considered for payment, have a direct effect on the revenue cycle of any diagnostic AI company in this space.
Connecting Coverage to Valuation Inputs
For any venture fund or family office looking at this space, the administrative record isn’t just a pile of compliance paperwork, it’s a set of direct inputs for your valuation model. In diagnostic AI, payment policy drives net revenue retention just as much as the product itself. You can have the most advanced, clinically proven AI solution on the planet, but it won’t hit its market potential if there isn’t a clear and favorable reimbursement path. It’s that simple. Look at the competitive picture with a company like Cleerly, which is also in the plaque quantification game. Cleerly has plenty of private funding, but its long-term valuation will absolutely depend on its success in getting and keeping favorable payment policies. Without a stable reimbursement strategy, financial projections become guesswork which kills investor confidence and craters valuation multiples. This is why you have to read the FDA CDRH clearance record (which just sets the potential use cases) alongside the actual coding and coverage decisions. The FDA 510(k) database for diagnostic AI devices might show a broad clearance, but if the MACs only reimburse for a narrow slice of that, your real addressable market is much smaller than you think. The gap between regulatory clearance and payment policy is where valuations are made or broken.
Diligence Checklist for FFR-Based Assets
So when you’re doing diligence on an FFR-based asset, your valuation has to start with policy. That means getting deep into the administrative record and the clearance history. A structured approach should include:
- Review of National Coverage Determinations: Start with the big picture CMS policies for the whole diagnostic category.
- Analysis of Local Coverage Determinations (LCDs) and Articles (LCAs): You need to tear down documents like WPS A59813 version 6 and LCD L39913 to find the specific coding rules, effective dates, and any coverage limits.
- FDA CDRH Clearance Documents: Confirm exactly what indications were cleared and under what conditions. This is the absolute ceiling for what can be reimbursed.
- Impact of Coding Changes: What do upcoming changes, like the ones for January 1, 2026, actually mean for billing and future revenue? Run the numbers.
- Competitive Reimbursement Field: Figure out how competitors, like Cleerly’s plaque quantification, are working through the payment rules. Are they getting paid? How?
Every one of these coverage records needs to be in the valuation file for an FFR-based asset. The administrative paper trail isn’t some secondary detail, it’s what’s driving market momentum and deal flow in healthcare AI right now. Any investor who blows past these policy details is going to get the valuation wrong. CMS National Coverage Determinations search
Frequently Asked Questions
What role does FDA clearance play in the valuation of diagnostic AI assets?
FDA CDRH clearances define the permissible medical uses for diagnostic AI devices. While essential for establishing the clinical scope, clearance alone does not guarantee payment or market potential, as reimbursement policies significantly influence valuation.
How do local Medicare Administrative Contractors (MACs) influence the valuation of diagnostic AI assets?
MACs like WPS Government Health Administrators translate national policy into actionable coding and billing guidance through documents such as LCDs and articles. These documents provide crucial insights into future revenue streams by detailing specific billing practices and covered indications, directly impacting valuation.
Why is the administrative record, including coding guidance and local coverage determinations, as critical as clinical trial data for valuing diagnostic AI?
The administrative record shapes net revenue retention by determining payment policies and reimbursement pathways. Without clear and favorable reimbursement, even clinically validated diagnostic AI solutions cannot achieve full market potential, making it a first-class valuation variable alongside clinical efficacy.
How do changes in coding documents, such as those effective January 1, 2026, impact the revenue cycle for diagnostic AI companies?
Changes in coding documents, like the migration of plaque analysis billing to a new CPT code, refine administrative processes for established diagnostic categories. While not necessarily enlarging the covered market, these changes directly influence billing practices and the revenue cycle for diagnostic AI companies.